deCODE genetics Inc.
Sturlugata 8
Reykjavik,
101
Iceland - Map
Phone: 354 570 1900
Fax: 354 570 1903
Web Site: http://www.decode.com
| deCODE genetics, Inc., a bio-pharmaceutical company, develops and markets products for the treatment, diagnosis, and prevention of common diseases. It offers DNA-based diagnostic tests to detect single-letter variations in the human genome (SNPs), such as deCODE T2, which detects SNPs associated with risk of type 2 diabetes; and deCODE AF, which detects SNPs associated with risk of atrial fibrillation and stroke. The company also provides deCODE MI, which detects SNPs associated with early-onset heart attack/myocardial infarction; deCODE Glaucoma, which detects SNPs linked to risk of exfoliation glaucoma; and deCODE BreastCancer, which detects SNPs linked to risk of various forms of breast cancer. In addition, its lead drug development programs include DG041 for the prevention of arterial thrombosis, DG051 for the prevention of heart attack has completed Phase IIa clinical studies; DG031 for the prevention of heart attack has completed reformulation. Further, the companys DNA-based risk diagnostic tests in development include melanoma, basal cell cancer, bladder cancer, and lung cancer. Furthermore, it provides contract genotyping services; deCODEme, a consumer genetic analysis service; deCODEme Cardio for cardiovascular-related diseases; and deCODEme Cancer for several common types of cancer. The company serves pharmaceutical companies, biotechnology firms, pharmacogenomics companies, government institutions, research consortia, academic institutions, universities, and other research institutions in the United States and Europe. It has a strategic alliance with Illumina, Inc. to develop and commercialize molecular diagnostic products. deCODE genetics, Inc. was founded in 1996 and is headquartered in Reykjavik, Iceland. On November 16, 2009, deCODE genetics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Kari Stefansson M.D., 60
Co-Founder, Chairman, Chief Exec. Officer and Pres |
N/A
| N/A | Mr. Lance Thibault , 42
Chief Financial Officer, Principal Accounting Officer and Treasurer |
N/A
| N/A | Mr. Axel Nielsen , 44
Chief Operating Officer |
$
365.00K | N/A | Dr. Mark Gurney Ph.D., 54
Sr. VP of Drug Discovery & Devel. |
N/A
| N/A | Mr. Jakob Sigurðsson , 45
Sr. VP of Corp. Devel. |
$
365.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.003 (8.57%) 
Profile
